In a recent consensus paper by the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, it was concluded that while MRI and TSPO-positive PET are emerging as potential biomarkers of chronic active lesions in MS, these biomarkers do not have equivalent sensitivity and specificity to histopathological findings. This evidence concerns the gene TSPO and myeloid sarcoma.